Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

PTEN profiling

Jonathan B Weitzman

Author Affiliations

Genome Biology 2001, 2:spotlight-20011107-01  doi:10.1186/gb-spotlight-20011107-01

The electronic version of this article is the complete one and can be found online at:


Published:7 November 2001

© 2001 BioMed Central Ltd

Research news

PTEN is a tumour suppressor that may act by de-phosphorylating another signaling molecule, phosphatidyl inositol (PI) 3-kinase. In the November 6 Proceedings of the National Academy of Science, Javor Stolarov and colleagues from the Cold Spring Harbor Laboratory describe the generation of an inducible system to examine PTEN function (Proc Natl Acad Sci USA 2001, 98:13043-13048). They describe a retroviral-based experimental procedure to create regulated ecdysone-inducible expression of PTEN in a human glioblastoma cell line. They then examined the effects of PTEN induction on gene expression profiles using cDNA microarrays (containing 14,000 IMAGE Consortium clones) and compared the results with cells that were treated with the drug LY294002, an inhibitor of PI 3-kinase. Stolarov and colleagues identified both down-regulated and up-regulated genes, including those involved in growth control (such as transforming growth factor β, TGF-β) and cholesterol biosynthesis (for example, HMG-CoA synthase). These genes were also affected by LY294002 treatment, confirming that PTEN functions via the PI 3-kinase pathway.

References

  1. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

    PubMed Abstract | Publisher Full Text OpenURL

  2. [http://www.pnas.org] webcite

    Proceedings of the National Academy of Sciences

  3. [http://www.cshl.org] webcite

    Cold Spring Harbor Laboratory

  4. Inducible gene expression in mammalian cells and transgenic mice.

    PubMed Abstract | Publisher Full Text OpenURL